Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | SETDB1 | Q15047 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2262218 | 0.88 | NPC1 (0.52) | NPC1RAB9AMCL1P2RX7SMN1; SMN2 | |
| SCHEMBL6318135 | 0.81 | MCL1 (0.61) | NPC1RAB9AMCL1P2RX7SMN1; SMN2 | |
| SCHEMBL2263200 | 0.78 | MCL1 (0.70) | NPC1RAB9AMCL1SMN1; SMN2LMNA | |
| SCHEMBL2262207 | 0.77 | MCL1 (0.59) | NPC1RAB9AMCL1LMNAHTT | |
| SCHEMBL2266083 | 0.77 | P2RX7 (0.54) | MCL1P2RX7KCNH2ALDH1A1 | |
| SCHEMBL2267520 | 0.76 | MCL1 (0.54) | NPC1RAB9AMCL1P2RX7SMN1; SMN2 | |
| SCHEMBL12366175 | 0.76 | NPC1 (0.56) | NPC1RAB9AP2RX7SMN1; SMN2LMNA | |
| SCHEMBL11872322 | 0.76 | NPC1 (0.52) | NPC1RAB9AP2RX7SMN1; SMN2HTT | |
| SCHEMBL6317268 | 0.76 | MCL1 (0.67) | MCL1LMNAALDH1A1 | |
| SCHEMBL1520513 | 0.76 | NPC1 (0.59) | NPC1RAB9AP2RX7SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998986-B2 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998986-B2 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20030181420-A1 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | EXELIXIS, INC. | 2003-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181420-A1 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | NR1H2, NR1H3, NCOA1 | NPC1 615/4885RAB9A 4166/4885MCL1 3083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.